AstraZeneca restarts production at Indian site but meropenem probe continues
This article was originally published in Scrip
Executive Summary
AstraZeneca has resumed production at its Indian steriles facility, but said that it had voluntarily recalled products worth over Rs26 million ($478,000) after the unit did not satisfy the firm's own global quality audit.